Cervical Intraepithelial Neoplasia News and Research

RSS
HPV co-testing prospect for HIV-infected women

HPV co-testing prospect for HIV-infected women

Study: HIV-infected women less likely to develop cervical cancer

Study: HIV-infected women less likely to develop cervical cancer

CAP/ASCCP LAST Project recommendations for better diagnosis of HPV-associated lesions

CAP/ASCCP LAST Project recommendations for better diagnosis of HPV-associated lesions

Cellular source of cervical cancer found

Cellular source of cervical cancer found

Enrollment complete in Advaxis’ ADXS-HPV Phase 2 study on CIN 2/3

Enrollment complete in Advaxis’ ADXS-HPV Phase 2 study on CIN 2/3

Advaxis completes ADXS-PSA prostate cancer construct pre-IND meeting with the FDA

Advaxis completes ADXS-PSA prostate cancer construct pre-IND meeting with the FDA

Advaxis submits protocol revision for ADXS-HPV CIN Phase II study

Advaxis submits protocol revision for ADXS-HPV CIN Phase II study

Roche signs agreement to acquire mtm laboratories

Roche signs agreement to acquire mtm laboratories

Inovio reports strong immune responses with VGX-3100 vaccine for cervical dysplasia and cancer

Inovio reports strong immune responses with VGX-3100 vaccine for cervical dysplasia and cancer

Enrollment complete in Advaxis ADXS-HPV Phase II CIN study

Enrollment complete in Advaxis ADXS-HPV Phase II CIN study

Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer

Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Program reduces cervical cancer deaths among HIV-infected women in Zambia

Program reduces cervical cancer deaths among HIV-infected women in Zambia

Gen-Probe's APTIMA HPV assay effective for cervical cancer screening: FASE study

Gen-Probe's APTIMA HPV assay effective for cervical cancer screening: FASE study

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Annual conventional Pap smear is cost effective to reduce cancer incidence and mortality

Annual conventional Pap smear is cost effective to reduce cancer incidence and mortality

Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study

Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study

Advaxis completes enrollment of vanguard patient group in phase II clinical trial for cervical intraepithelial neoplasia

Advaxis completes enrollment of vanguard patient group in phase II clinical trial for cervical intraepithelial neoplasia